May 2018 Issue of MMM

May 2018 Issue of MMM

Go Figure

Infographic | A closer look at co-pay coupons and programs

Intriguing data on the economics and impact of co-pay coupons and programs

Editor's Desk

Data-driven. Obsessive. A little pushy. Meet this year's Top 40 Healthcare Transformers

Those on the vanguard of transformation include a number of upstarts and veteran gurus taking on historic challenges plaguing health data.

Digital Edition

Read the May 2018 Digital Edition

Read the May 2018 issue in its entirety.


McCaskill takes aim at DTC ad tax deduction; measure expected to face stiff resistance

Pharma companies are likely to put up aggressive resistance to the measure, introduced earlier this month.

Top 40 Healthcare Transformers of 2018

Here are the 40 upstarts and veterans who are transforming the healthcare industry.

Partner Forum

Marketers share how they use ad safety tech to help pharma clients feel comfortable

Marketers discuss the role of ad safety tech in helping pharma clients feel comfortable with ads in non-endemic media.


Health brands need to consider the human side of patients, HCPs, and stakeholders

Croom Lawrence and Kent Groves of Merkle Health explain being human.

How pharma and healthcare shifted strategies post-blockbuster drug success

Remedy Health Media's Mike Collins discusses ways pharma and healthcare companies have shifted their strategies in the years after the success of blockbuster drugs.

Private View

6 campaigns using real patients as advocates for orphan drugs

Dawn Hastings, associate creative director, Dudnyk, says using patients in campaigns for orphan drugs makes a brand's audience feel obligated to act.

At Work With

Rbb Communications' Srikant Ramaswami on yoga, 'think time,' and his mentors

Rbb Communications' EVP of global and emerging markets, healthcare Srikant Ramaswami discusses how he keeps sane with his busy schedule and what inspires him.

Back Talk

Drugs' value to patients eclipsed by price tags

Like other sectors, pharma is experiencing upheavals no one predicted, and as a result, drugs are being reviled for their price tags, rather than praised ...